Evaluating Hypoglycemic Risk of Two Basal Insulin Delivery Methods for Type 1 Diabetes: A Comparison of Tresiba Insulin against Continuous Subcutaneous Insulin Infusion using Data from Continuous Glucose Monitors
Type 1 diabetes is a chronic disease that cannot be cured, but instead it must be managed through exogenous insulin replacement. Different insulin treatment regimens are available, and understanding the differences is paramount to making informed clinical decisions. This study compared two different insulin treatments, Tresiba insulin and continuous subcutaneous insulin infusion (CSII), in terms of their risk of inducing hypoglycemia (blood glucose less than 70) over the 24 hours of the day. When compared across the full 24 hours, the study team did not detect statistically significant differences, but when broken into different time intervals, Tresiba was associated with less hypoglycemia in the early morning hours and late evening hours. Simulation studies were also performed to investigate the affect that population heterogeneity and dependence structure misspecification have on study results.